|Tuesday, 11 April 2017, 11:42 HKT/SGT|
|Easy to Drink Bergamot Flavor|
TOKYO, Apr 11, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that, approaching the 65th anniversary of its Chocola BB brand, it will launch Chocola BB Gold Rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on Monday, April 17. Chocola BB Gold Rich is a luxurious combination of 16 active ingredients, the highest number in the Chocola BB series. It contains active ingredients including B-complex vitamins and taurine 1500mg to help a fatigued body produce energy, and six natural herbs carefully selected by female developers to please female consumers, including angelica acutiloba, ginseng, and royal jelly. The bergamot orange flavor, which is also used in Earl Grey tea and other products, is easy to drink, and the gold and pink packaging is elegantly designed to give off a sense of luxury. This boxed supplement drink from the Chocola BB brand has been designed to be approachable for female consumers.
In recent years, along with the increasing social advancement of women, the market catering to female supplement drink consumers is also growing. Additionally, consumers drink different products depending on their level of fatigue. This product is designed to respond to the needs of women who want a high performance drink. Chocola BB Gold Rich is a speedy fatigue reliever perfect for busy women in the office or at home.
The Chocola BB supplement drink series includes Chocola BB Light 2 for day-to-day fatigue, Chocola BB Royal 2 for extreme fatigue, and Chocola BB Hyper for weak constitutions, all of which are marketed as designated quasi-drug products designed to help relieve fatigue.
Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Apr 11, 2017 11:42 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.